All Drug Discovery Processes articles
-
ArticleOne sample. One shot. The pressure on sample preparation in drug discovery
In drug discovery, a failed sample run is not just a setback – it can mean months of lost work and significant cost. At Analytica 2026, three Eppendorf experts explain how the right tools, workflows and mindset are changing that.
-
NewsSafer diazo compound synthesis advances medicinal chemistry capabilities
Researchers at Tokyo University of Science have developed a safer synthetic route to β-heteroatom-substituted diazo esters, eliminating the need for toxic diazomethane. The azide-to-diazo conversion method uses mild conditions and readily available starting materials, potentially streamlining early-stage drug discovery and compound library synthesis.
-
ArticleThe scale divide: competing strategies in AI drug discovery
Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a handful of parameters, with early results raising questions about which will deliver.
-
ArticleWhen scale meets insight: reinventing SPR for the future of drug discovery
Carterra’s new 48-channel SPR platform reimagines throughput, automation and data quality for modern discovery workflows.
-
ArticleDrug Target Review launches new website designed for drug discovery professionals
Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that provides full access to premium analysis, reports and expert commentary.
-
NewsAAX Biotech and evitria partner on antibody development
AAX Biotech has partnered with evitria AG to expand access to its Opti-mAb® platform, enabling earlier integration of stability-enhancing technology into antibody candidate design and multispecific format development.
-
NewsNew method streamlines C–N bond formation for amine synthesis
Researchers at the University of Wisconsin–Madison have reported a new approach to forming carbon–nitrogen bonds, a critical step in the synthesis of amines widely used in pharmaceuticals, agrochemicals and polymers.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsELRIG launches inaugural US drug discovery conference 2026 in Cambridge, MA
ELRIG has announced Drug Discovery USA 2026, a free two-day conference at Pfizer Cambridge bringing together international researchers to address challenging therapeutic targets through advances in multifunctional small molecules and novel biologics.
-
NewsOntario invests $3.1M in next-generation cancer therapeutics
The Ontario Institute for Cancer Research has awarded $3.1 million to four provincial research teams developing novel cancer therapies designed to overcome drug resistance and reduce treatment-related toxicity.
-
NewsMassey Cancer Center funds drug discovery projects targeting Hsp27-CerS1 and ferroptosis pathways
The VCU Massey Comprehensive Cancer Center has awarded $50,000 each to two innovative drug discovery projects through its collaborative programme with Sanford Burnham Prebys Medical Discovery Institute.
-
ArticleOperational data: the hidden driver of faster drug discovery
The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.
-
WebinarManufacturing the Future: From N=1 Personalized CRISPR Therapy to Scalable Precision Genomic Medicine
How biotech leaders are turning one-off CRISPR breakthroughs into scalable, regulatory-ready therapies.
-
ArticleFrom fragments to maps: scaling drug–target interaction data
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
News$13.9M UCLA study maps autism and schizophrenia biology for drug discovery
A $13.9 million UCLA-led research programme will use CRISPR gene editing and ‘cell villages’ to systematically map the molecular differences underlying autism and schizophrenia, addressing the absence of medicines targeting the biological roots of both conditions.
-
InterviewPhysics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
-
ArticleAnticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
-
ArticleKMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as highly selective immunotherapy targets across plasma cell dyscrasias.